-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-Revance Announces U.S. FDA Acceptance Of Supplemental Biologics License Application (Sbla) For Daxxify® (Daxibotulinumtoxina-Lanm) For Injection For The Treatment Of Cervical Dystonia

Reuters · 01/06/2023 18:01
BRIEF-Revance Announces U.S. FDA Acceptance Of Supplemental Biologics License Application (Sbla) For Daxxify® (Daxibotulinumtoxina-Lanm) For Injection For The Treatment Of Cervical Dystonia

- Revance Therapeutics Inc RVNC.O:

  • REVANCE ANNOUNCES U.S. FDA ACCEPTANCE OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR DAXXIFY® (DAXIBOTULINUMTOXINA-LANM) FOR INJECTION FOR THE TREATMENT OF CERVICAL DYSTONIA

  • REVANCE THERAPEUTICS INC - PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE OF AUGUST 19, 2023

  • REVANCE THERAPEUTICS INC - DAXXIFY WAS SHOWN TO BE EFFECTIVE, GENERALLY SAFE AND WELL TOLERATED ACROSS BOTH DOSE GROUPS, 125U AND 250U

Source text for Eikon: ID:

Further company coverage: RVNC.O


((Reuters.Briefs@thomsonreuters.com;;))